Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease

被引：109

作者：

Ho P.M. ^{[1
,2
]}

Magid D.J. ^{[3
,4
]}

Masoudi F.A. ^{[2
,5
]}

McClure D.L. ^{[4
]}

Rumsfeld J.S. ^{[1
,2
]}

机构：

[1] Cardiology Section, Denver VA Medical Center, Denver, CO

[2] Department of Medicine, University of Colorado Health Sciences Center, Denver, CO

[3] Department of Biometrics and Preventive Medicine, University of Colorado Health Sciences Center, Denver, CO

[4] Clinical Research Unit, Kaiser Permanente of Colorado, Denver, CO

[5] Department of Medicine, Denver Health Medical Center, Denver, CO

来源：

BMC Cardiovascular Disorders | / 6卷 / 1期

关键词：

Ischemic Heart Disease; Medication Adherence; Adherent Patient; Statin Medication; Chronic Ischemic Heart Disease;

D O I：

10.1186/1471-2261-6-48

中图分类号：

学科分类号：

摘要：

Background: Patients with diabetes and ischemic heart disease (IHD) are at high risk for adverse cardiac outcomes. Clinical practice guidelines recommend multiple cardioprotective medications to reduce recurrent events. We evaluated the association between cardioprotective medication adherence and mortality among patients with diabetes and IHD. Methods: In a retrospective cohort study of 3,998 patients with diabetes and IHD, we evaluated use of ACE inhibitors or angiotensin receptor blockers, β-blockers, and statin medications. Receipt of cardioprotective medications was based on filled prescriptions. Medication adherence was calculated as the proportion of days covered (PDC) for filled prescriptions. The primary outcome of interest was all-cause mortality. Results: The majority of patients (92.8%) received at least 1 cardioprotective medication. Patients receiving any medications had lower unadjusted mortality rates compared to patients not receiving any medications (7.9% vs. 11.5%; p = 0.03). In multivariable analysis, receipt of any cardioprotective medication remained associated with lower all-cause mortality (OR 0.65; 95% CI 0.43-0.99). Among patients receiving cardioprotective medications, the majority (80.3%) were adherent (PDC ≥ 0.80). Adherent patients had lower unadjusted mortality rates (6.7% vs. 12.1%; p < 0.01). In multivariable analysis, medication adherence remained associated with lower all-cause mortality (OR 0.52; 95% CI 0.39-0.69) compared to non-adherence. In contrast, there was no mortality difference between patients receiving cardioprotective medications who were non-adherent compared to patients not receiving any medications (OR 1.01; 95% CI 0.64-1.61). Conclusion: In conclusion, medication adherence is associated with improved outcomes among patients with diabetes and IHD. Quality improvement interventions are needed to increase medication adherence in order for patients to maximize the benefit of cardioprotective medications. © 2006 Ho et al; licensee BioMed Central Ltd.

引用

共 31 条

[1] Selby J.V., Peng T., Karter A.J., Alexander M., Sidney S., Lian J., Arnold A., Pettitt D., High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population, Am J Manag Care, 10, 2 PART 2, pp. 163-170, (2004)
[2] Heart Disease and Stroke Statistics - 2006 Update, (2006)
[3] Gibbons R.J., Abrams J., Chatterjee K., Daley J., Deedwania P.C., Douglas J.S., Ferguson Jr. T.B., Fihn S.D., Fraker Jr. T.D., Gardin J.M., O'Rourke R.A., Pasternak R.C., Williams S.V., ACC/AHA 2002 Guidelines Update for the Management of Patients With Chronic Stable Angina: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients With Chronic Stable Angina), (2002)
[4] Standards of medical care in diabetes, Diabetes Care, 28, 1, (2005)
[5] Adherence to Long-term Therapies: Evidence for Action, (2003)
[6] Newby L.K., LaPointe N.M.A., Chen A.Y., Kramer J.M., Hammill B.G., DeLong E.R., Muhlbaier L.H., Califf R.M., Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease, Circulation, 113, pp. 203-212, (2006)
[7] Jackevicius C.A., Mamdani M., Tu J.V., Adherence with statin therapy in elderly patients with and without acute coronary syndromes, JAMA, 288, 4, pp. 462-467, (2002)
[8] Petersen L.A., Wright S., Normand S.L., Daley J., Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database, J Gen Intern Med, 14, 9, pp. 555-558, (1999)
[9] Steiner J.F., Koepsell T.D., Fihn S.D., Inui T.S., A general method of compliance assessment using centralized pharmacy records, Med Care, 4, pp. 814-823, (1988)
[10] Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., Avorn J., Long-term persistence in use of statin therapy in elderly patients, JAMA, 288, pp. 455-461, (2002)

← 1 2 3 4 →